 Michael Allen
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychomotor Agitation | 25 | 2017 | 69 | 3.780 |
Why?
| | Antipsychotic Agents | 23 | 2017 | 211 | 3.390 |
Why?
| | Emergency Services, Psychiatric | 16 | 2019 | 31 | 2.390 |
Why?
| | Suicide, Attempted | 23 | 2025 | 426 | 2.170 |
Why?
| | Suicidal Ideation | 15 | 2025 | 583 | 2.150 |
Why?
| | Bipolar Disorder | 24 | 2012 | 291 | 2.110 |
Why?
| | Psychotic Disorders | 11 | 2016 | 192 | 1.370 |
Why?
| | Schizophrenia | 8 | 2017 | 464 | 1.340 |
Why?
| | Emergency Service, Hospital | 17 | 2021 | 2383 | 1.260 |
Why?
| | Mental Disorders | 12 | 2017 | 1169 | 1.120 |
Why?
| | Mass Screening | 16 | 2023 | 1361 | 1.050 |
Why?
| | Suicide | 20 | 2023 | 729 | 1.000 |
Why?
| | Benzodiazepines | 9 | 2016 | 168 | 0.980 |
Why?
| | Restraint, Physical | 6 | 2016 | 75 | 0.980 |
Why?
| | Emergency Medicine | 3 | 2017 | 282 | 0.840 |
Why?
| | Aggression | 4 | 2016 | 180 | 0.790 |
Why?
| | Risk Management | 3 | 2019 | 82 | 0.750 |
Why?
| | Haloperidol | 5 | 2016 | 32 | 0.750 |
Why?
| | Antimanic Agents | 5 | 2009 | 19 | 0.730 |
Why?
| | Psychological Tests | 2 | 2017 | 130 | 0.660 |
Why?
| | Advisory Committees | 4 | 2017 | 229 | 0.650 |
Why?
| | Promethazine | 3 | 2016 | 5 | 0.650 |
Why?
| | Emergency Medical Services | 6 | 2016 | 684 | 0.640 |
Why?
| | Telephone | 2 | 2019 | 177 | 0.590 |
Why?
| | Professional-Patient Relations | 1 | 2019 | 147 | 0.550 |
Why?
| | Psychiatric Status Rating Scales | 14 | 2016 | 533 | 0.530 |
Why?
| | Loxapine | 3 | 2012 | 4 | 0.520 |
Why?
| | Lurasidone Hydrochloride | 1 | 2017 | 1 | 0.520 |
Why?
| | Program Development | 1 | 2019 | 368 | 0.510 |
Why?
| | Medical History Taking | 2 | 2017 | 117 | 0.510 |
Why?
| | Surgical Clearance | 1 | 2017 | 6 | 0.500 |
Why?
| | Evidence-Based Medicine | 3 | 2017 | 740 | 0.490 |
Why?
| | Physical Examination | 2 | 2017 | 244 | 0.470 |
Why?
| | Risk Assessment | 11 | 2019 | 3752 | 0.470 |
Why?
| | Injections, Intramuscular | 7 | 2008 | 146 | 0.460 |
Why?
| | Anticonvulsants | 2 | 2009 | 246 | 0.410 |
Why?
| | Humans | 88 | 2025 | 145763 | 0.410 |
Why?
| | Adult | 45 | 2025 | 40872 | 0.410 |
Why?
| | Lithium Carbonate | 2 | 2009 | 6 | 0.380 |
Why?
| | Communication | 1 | 2019 | 977 | 0.380 |
Why?
| | Dibenzothiazepines | 2 | 2009 | 18 | 0.370 |
Why?
| | Psoriasis | 3 | 2023 | 115 | 0.370 |
Why?
| | Self-Injurious Behavior | 4 | 2021 | 141 | 0.370 |
Why?
| | Acute Disease | 9 | 2017 | 1036 | 0.350 |
Why?
| | Depression | 4 | 2023 | 1557 | 0.340 |
Why?
| | Valproic Acid | 3 | 2006 | 49 | 0.340 |
Why?
| | Substance-Related Disorders | 6 | 2008 | 1102 | 0.330 |
Why?
| | Observation | 3 | 2009 | 54 | 0.320 |
Why?
| | Middle Aged | 30 | 2025 | 36302 | 0.320 |
Why?
| | Male | 44 | 2025 | 73003 | 0.300 |
Why?
| | Tranquilizing Agents | 2 | 2008 | 2 | 0.300 |
Why?
| | Double-Blind Method | 7 | 2025 | 2064 | 0.280 |
Why?
| | Female | 44 | 2025 | 79035 | 0.280 |
Why?
| | Violence | 3 | 2011 | 280 | 0.270 |
Why?
| | Nicotine | 1 | 2011 | 331 | 0.270 |
Why?
| | Smoking | 3 | 2011 | 1477 | 0.270 |
Why?
| | Comorbidity | 8 | 2019 | 1662 | 0.260 |
Why?
| | Prospective Studies | 13 | 2023 | 8075 | 0.250 |
Why?
| | Borderline Personality Disorder | 1 | 2007 | 14 | 0.250 |
Why?
| | Disease Management | 2 | 2016 | 653 | 0.250 |
Why?
| | International Cooperation | 1 | 2007 | 197 | 0.250 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 1043 | 0.240 |
Why?
| | Primary Health Care | 6 | 2023 | 1737 | 0.240 |
Why?
| | Informed Consent | 1 | 2008 | 199 | 0.240 |
Why?
| | Risk Factors | 13 | 2023 | 10917 | 0.240 |
Why?
| | Psychometrics | 4 | 2015 | 731 | 0.230 |
Why?
| | Academic Medical Centers | 2 | 2011 | 554 | 0.230 |
Why?
| | Guidelines as Topic | 1 | 2007 | 268 | 0.230 |
Why?
| | United States | 17 | 2021 | 16123 | 0.220 |
Why?
| | Alcoholism | 2 | 2015 | 826 | 0.210 |
Why?
| | Midazolam | 3 | 2016 | 73 | 0.200 |
Why?
| | Piperazines | 4 | 2007 | 375 | 0.200 |
Why?
| | Motivation | 2 | 2006 | 602 | 0.200 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 222 | 0.190 |
Why?
| | Mobile Applications | 1 | 2025 | 199 | 0.180 |
Why?
| | Quality of Health Care | 1 | 2007 | 693 | 0.180 |
Why?
| | Young Adult | 9 | 2021 | 14251 | 0.180 |
Why?
| | Adolescent | 15 | 2021 | 22573 | 0.170 |
Why?
| | Thiazoles | 3 | 2007 | 142 | 0.170 |
Why?
| | Cost-Benefit Analysis | 3 | 2022 | 644 | 0.170 |
Why?
| | Activities of Daily Living | 1 | 2005 | 444 | 0.170 |
Why?
| | Inpatients | 1 | 2025 | 553 | 0.160 |
Why?
| | Pilot Projects | 2 | 2019 | 1897 | 0.160 |
Why?
| | Patient Satisfaction | 1 | 2005 | 712 | 0.160 |
Why?
| | Preventive Psychiatry | 1 | 2019 | 5 | 0.150 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1430 | 0.150 |
Why?
| | Schizophrenic Psychology | 2 | 2011 | 99 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2016 | 1751 | 0.140 |
Why?
| | Quetiapine Fumarate | 2 | 2009 | 26 | 0.140 |
Why?
| | Lorazepam | 2 | 2016 | 26 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 3 | 2015 | 2399 | 0.140 |
Why?
| | Health Services Research | 2 | 2013 | 391 | 0.140 |
Why?
| | Cognition Disorders | 1 | 2003 | 544 | 0.140 |
Why?
| | Hospitalization | 5 | 2021 | 2460 | 0.140 |
Why?
| | Consensus | 2 | 2017 | 479 | 0.130 |
Why?
| | Aged | 11 | 2019 | 26215 | 0.130 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 3 | 2008 | 232 | 0.130 |
Why?
| | Neuropsychological Tests | 1 | 2002 | 1137 | 0.130 |
Why?
| | Utilization Review | 2 | 2008 | 39 | 0.130 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 782 | 0.120 |
Why?
| | Risperidone | 2 | 2007 | 30 | 0.120 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 1582 | 0.120 |
Why?
| | Quality of Life | 2 | 2008 | 3210 | 0.120 |
Why?
| | Combined Modality Therapy | 4 | 2017 | 1270 | 0.120 |
Why?
| | Severity of Illness Index | 7 | 2008 | 2933 | 0.120 |
Why?
| | Altitude Sickness | 1 | 2017 | 141 | 0.120 |
Why?
| | Antidepressive Agents, Second-Generation | 2 | 2007 | 46 | 0.120 |
Why?
| | Reproducibility of Results | 4 | 2015 | 3416 | 0.120 |
Why?
| | Administration, Inhalation | 3 | 2012 | 571 | 0.120 |
Why?
| | Treatment Outcome | 8 | 2012 | 11793 | 0.110 |
Why?
| | Aftercare | 1 | 2017 | 222 | 0.110 |
Why?
| | Antidepressive Agents | 3 | 2008 | 242 | 0.110 |
Why?
| | Surveys and Questionnaires | 6 | 2021 | 6085 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2011 | 2028 | 0.110 |
Why?
| | Longitudinal Studies | 6 | 2011 | 2967 | 0.110 |
Why?
| | Patient Admission | 2 | 2008 | 220 | 0.110 |
Why?
| | Quinolones | 2 | 2007 | 204 | 0.110 |
Why?
| | Patient Discharge | 1 | 2021 | 995 | 0.110 |
Why?
| | Referral and Consultation | 2 | 2019 | 868 | 0.110 |
Why?
| | Multicenter Studies as Topic | 3 | 2019 | 413 | 0.110 |
Why?
| | Adaptor Protein Complex 1 | 1 | 2014 | 5 | 0.100 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 30 | 0.100 |
Why?
| | Drug Administration Routes | 1 | 2013 | 42 | 0.100 |
Why?
| | Genetic Loci | 1 | 2015 | 267 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2018 | 480 | 0.100 |
Why?
| | Cognition | 1 | 2022 | 1271 | 0.100 |
Why?
| | Crisis Intervention | 2 | 2019 | 37 | 0.100 |
Why?
| | Altitude | 1 | 2017 | 463 | 0.100 |
Why?
| | Aged, 80 and over | 5 | 2017 | 8346 | 0.100 |
Why?
| | Age of Onset | 5 | 2008 | 557 | 0.090 |
Why?
| | Military Personnel | 1 | 2019 | 737 | 0.090 |
Why?
| | Hospitals, General | 2 | 2009 | 25 | 0.090 |
Why?
| | Safety | 3 | 2009 | 358 | 0.080 |
Why?
| | Psychiatric Department, Hospital | 1 | 2011 | 12 | 0.080 |
Why?
| | Transdermal Patch | 1 | 2011 | 15 | 0.080 |
Why?
| | Patient Safety | 1 | 2015 | 356 | 0.080 |
Why?
| | Chronic Disease | 1 | 2017 | 1812 | 0.080 |
Why?
| | Aerosols | 1 | 2011 | 145 | 0.080 |
Why?
| | Aripiprazole | 2 | 2007 | 20 | 0.080 |
Why?
| | Administration, Oral | 3 | 2008 | 867 | 0.080 |
Why?
| | Time Factors | 5 | 2011 | 7133 | 0.080 |
Why?
| | Emergencies | 2 | 2010 | 174 | 0.080 |
Why?
| | Family Health | 2 | 2009 | 191 | 0.080 |
Why?
| | Placebos | 2 | 2011 | 193 | 0.080 |
Why?
| | Circadian Rhythm Signaling Peptides and Proteins | 1 | 2009 | 2 | 0.080 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2010 | 148 | 0.080 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2010 | 47 | 0.080 |
Why?
| | Psychiatry | 2 | 2016 | 195 | 0.080 |
Why?
| | Interview, Psychological | 1 | 2009 | 95 | 0.070 |
Why?
| | Caregivers | 2 | 2009 | 1074 | 0.070 |
Why?
| | Affect | 2 | 2009 | 321 | 0.070 |
Why?
| | Colorado | 1 | 2019 | 4556 | 0.070 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 255 | 0.070 |
Why?
| | Diagnosis, Dual (Psychiatry) | 2 | 2006 | 39 | 0.070 |
Why?
| | Long-Term Care | 1 | 2009 | 118 | 0.070 |
Why?
| | Mental Health | 2 | 2013 | 796 | 0.070 |
Why?
| | Health Personnel | 2 | 2007 | 757 | 0.070 |
Why?
| | Health Status | 2 | 2019 | 835 | 0.070 |
Why?
| | Recreation | 1 | 2008 | 29 | 0.070 |
Why?
| | Personality Assessment | 2 | 2006 | 79 | 0.070 |
Why?
| | Demography | 2 | 2006 | 282 | 0.070 |
Why?
| | Hospitals, Psychiatric | 1 | 2008 | 29 | 0.070 |
Why?
| | Depressive Disorder | 3 | 2008 | 374 | 0.070 |
Why?
| | Physicians | 1 | 2017 | 956 | 0.070 |
Why?
| | Brazil | 1 | 2008 | 179 | 0.070 |
Why?
| | Internship and Residency | 2 | 2009 | 1269 | 0.070 |
Why?
| | Prevalence | 2 | 2013 | 2874 | 0.060 |
Why?
| | Nervous System Diseases | 1 | 2010 | 286 | 0.060 |
Why?
| | Treatment Refusal | 1 | 2008 | 99 | 0.060 |
Why?
| | Paroxetine | 1 | 2007 | 8 | 0.060 |
Why?
| | Follow-Up Studies | 6 | 2017 | 5428 | 0.060 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 342 | 0.060 |
Why?
| | Bupropion | 1 | 2007 | 48 | 0.060 |
Why?
| | Smoking Cessation | 1 | 2011 | 441 | 0.060 |
Why?
| | Switzerland | 1 | 2006 | 46 | 0.060 |
Why?
| | Narcotics | 1 | 2007 | 58 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2008 | 1512 | 0.060 |
Why?
| | Europe | 1 | 2007 | 421 | 0.060 |
Why?
| | Health Services Misuse | 1 | 2006 | 35 | 0.060 |
Why?
| | Fluphenazine | 1 | 2006 | 4 | 0.060 |
Why?
| | Alcohol-Related Disorders | 1 | 2007 | 121 | 0.060 |
Why?
| | Personal Satisfaction | 1 | 2008 | 219 | 0.060 |
Why?
| | Bayes Theorem | 1 | 2008 | 421 | 0.060 |
Why?
| | Lithium | 1 | 2005 | 40 | 0.060 |
Why?
| | Interrupted Time Series Analysis | 2 | 2015 | 75 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2010 | 2181 | 0.060 |
Why?
| | Recurrence | 2 | 2007 | 1139 | 0.060 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2005 | 62 | 0.050 |
Why?
| | Personality Inventory | 1 | 2005 | 134 | 0.050 |
Why?
| | Cocaine-Related Disorders | 1 | 2006 | 133 | 0.050 |
Why?
| | Curriculum | 2 | 2012 | 1074 | 0.050 |
Why?
| | Smartphone | 1 | 2025 | 107 | 0.050 |
Why?
| | Dangerous Behavior | 1 | 2004 | 16 | 0.050 |
Why?
| | Statistics as Topic | 1 | 2005 | 283 | 0.050 |
Why?
| | Biomedical Research | 1 | 2010 | 719 | 0.050 |
Why?
| | Urban Health Services | 1 | 2004 | 69 | 0.050 |
Why?
| | Linear Models | 1 | 2006 | 849 | 0.050 |
Why?
| | Marijuana Abuse | 1 | 2006 | 214 | 0.050 |
Why?
| | Incidence | 2 | 2011 | 2933 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2006 | 1300 | 0.050 |
Why?
| | Adalimumab | 1 | 2023 | 54 | 0.050 |
Why?
| | Age Factors | 3 | 2008 | 3346 | 0.050 |
Why?
| | Serotonin | 1 | 2005 | 298 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2023 | 220 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 615 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 971 | 0.040 |
Why?
| | Secondary Prevention | 2 | 2017 | 251 | 0.040 |
Why?
| | Anxiety Disorders | 1 | 2005 | 371 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2008 | 5922 | 0.040 |
Why?
| | Geriatric Assessment | 1 | 2003 | 240 | 0.040 |
Why?
| | Antibodies | 1 | 2023 | 397 | 0.040 |
Why?
| | Length of Stay | 1 | 2006 | 1350 | 0.040 |
Why?
| | Disclosure | 1 | 2019 | 84 | 0.040 |
Why?
| | Health Status Indicators | 1 | 2019 | 167 | 0.040 |
Why?
| | Inservice Training | 1 | 2019 | 118 | 0.030 |
Why?
| | DNA | 1 | 2005 | 1437 | 0.030 |
Why?
| | Postcards as Topic | 1 | 2017 | 2 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 2000 | 0.030 |
Why?
| | Rhode Island | 1 | 2017 | 31 | 0.030 |
Why?
| | Hotlines | 1 | 2017 | 35 | 0.030 |
Why?
| | Case Management | 1 | 2017 | 68 | 0.030 |
Why?
| | Substance Abuse Detection | 2 | 2009 | 110 | 0.030 |
Why?
| | Algorithms | 2 | 2019 | 1850 | 0.030 |
Why?
| | Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2015 | 5 | 0.030 |
Why?
| | Psychotherapy | 1 | 2017 | 182 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2004 | 1197 | 0.030 |
Why?
| | Cohort Studies | 4 | 2008 | 6032 | 0.030 |
Why?
| | Child | 3 | 2021 | 22739 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2016 | 173 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2015 | 75 | 0.030 |
Why?
| | Disease Progression | 1 | 2003 | 2865 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1327 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 120 | 0.030 |
Why?
| | Research Design | 2 | 2013 | 1139 | 0.030 |
Why?
| | Keratinocytes | 1 | 2015 | 249 | 0.030 |
Why?
| | Logistic Models | 2 | 2012 | 2139 | 0.020 |
Why?
| | Outpatients | 1 | 2017 | 447 | 0.020 |
Why?
| | Educational Status | 1 | 2015 | 470 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 302 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 334 | 0.020 |
Why?
| | Models, Statistical | 1 | 2017 | 672 | 0.020 |
Why?
| | Protein Transport | 1 | 2014 | 442 | 0.020 |
Why?
| | Societies | 1 | 2012 | 40 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 426 | 0.020 |
Why?
| | Professional Competence | 1 | 2012 | 91 | 0.020 |
Why?
| | Sex Factors | 2 | 2009 | 2110 | 0.020 |
Why?
| | Case-Control Studies | 2 | 2010 | 3634 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 1115 | 0.020 |
Why?
| | Protein Conformation | 1 | 2014 | 938 | 0.020 |
Why?
| | Animals | 1 | 2013 | 38097 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2131 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2015 | 740 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2883 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2011 | 536 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2009 | 35 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 297 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2009 | 150 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2010 | 507 | 0.020 |
Why?
| | Checklist | 1 | 2009 | 110 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 528 | 0.020 |
Why?
| | Cyclothymic Disorder | 1 | 2008 | 5 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2823 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 238 | 0.020 |
Why?
| | Gene Frequency | 1 | 2009 | 489 | 0.020 |
Why?
| | Self Concept | 1 | 2009 | 254 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 798 | 0.020 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 14 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2011 | 381 | 0.020 |
Why?
| | Documentation | 1 | 2009 | 199 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2805 | 0.020 |
Why?
| | Triage | 1 | 2009 | 250 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2009 | 336 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2009 | 463 | 0.010 |
Why?
| | Models, Psychological | 1 | 2008 | 294 | 0.010 |
Why?
| | Retrospective Studies | 3 | 2009 | 17325 | 0.010 |
Why?
| | Brain Injuries | 1 | 2010 | 507 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 2009 | 513 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1857 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 170 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2123 | 0.010 |
Why?
| | Drug Interactions | 1 | 2004 | 405 | 0.010 |
Why?
| | Forecasting | 1 | 2004 | 390 | 0.010 |
Why?
| | Drug Overdose | 1 | 2007 | 375 | 0.010 |
Why?
| | Phenotype | 1 | 2010 | 3170 | 0.010 |
Why?
| | Research | 1 | 2004 | 431 | 0.010 |
Why?
| | Alcohol Drinking | 1 | 2007 | 843 | 0.010 |
Why?
| | Critical Care | 1 | 2005 | 702 | 0.010 |
Why?
| | Pregnancy | 1 | 2010 | 7215 | 0.010 |
Why?
|
|
Allen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|